（一）本组简介
目前本组共有教师4名（博士生导师2名、硕士生导师2名）。课题组主要从事疫苗临床试验与传染病流行病学研究，建立了完善的研究平台，并积累了丰富的实践经验，目前在研项目包括宫颈癌系列疫苗、冻干水痘减毒活疫苗（VZV-7D）、新冠系列疫苗、戊型肝炎疫苗等国际一类创新疫苗的系列临床研究，HPV/CMV感染及相关大型流行病学队列研究。已经成功设计并实施4种创新型疫苗的多中心随机双盲对照Ⅲ期临床试验，其中戊肝疫苗已完成Ⅲ期临床试验并于2012年上市；二价宫颈癌疫苗已完成Ⅲ期临床试验并于2019年上市；九价宫颈癌疫苗Ⅲ期临床试验五个研究现场已完成入组，进入病例收集阶段；鼻喷流感病毒载体新冠肺炎疫苗Ⅲ期为海外多中心临床试验，已在菲律宾、南非、哥伦比亚和越南四个国家完成试验，并于2022年获批紧急使用。本组主持或承担多个国家863计划项目、重大传染病防治国家科技重大专项、国家自然科学基金项目、福建省科技重大专项和横向课题等。近年来研究成果发表在N Engl J Med（IF=176.079）、Lancet（IF=202.731）、Lancet Respir Med（IF=102.642）、Lancet Infect Dis（IF=71.421）、Lancet Reg Health West Pac（IF=8.559）、Emerg Microbes Infect（IF=19.568）、Hepatology（IF=17.298）、J Natl Cancer Inst（IF=11.816）、Clin Infect Dis（IF=20.999）等国际顶级期刊上。
（二）导师
张军、吴婷、黄守杰、苏迎盈
（三）正在开展的项目
1. 重组人乳头瘤病毒（HPV）6/11/16/18/31/33/45/52/58型九价疫苗的有效性随机对照试验（RCT）
2. 重组人乳头瘤病毒（HPV）6/11/16/18/31/33/45/52/58型九价疫苗与已上市九价疫苗（佳达修®9）免疫原性比较临床试验（RCT）
3. 重组人乳头瘤病毒（HPV）6/11/16/18/31/33/45/52/58型九价疫苗在9-17岁健康人群免疫原性桥接临床试验（RCT）
4. 鼻喷流感病毒载体新冠肺炎疫苗随机对照试验（RCT）
5. 冻干水痘减毒活疫苗（VZV-7D）的随机对照试验（RCT）
6. 重组人乳头瘤病毒（HPV）6/11型双价疫苗的随机对照试验（RCT）
7. 巨细胞病毒（CMV）感染危险因素的队列研究
8. 福建省人乳头瘤病毒疫苗卫生经济学评价及应用策略研究
9. 慢性肝炎及肝硬化患者接种重组戊型肝炎疫苗（大肠埃希菌）益可宁的开放性临床试验
（四）近年来发表的部分文章
1. Jun Zhang*, Xue-Feng Zhang#, Shou-Jie Huang, Ting Wu, Yue-Mei Hu, Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-Hui Liu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan, Yi-Min Li, J. Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu*, and Ning-Shao Xia*. Long-Term Efficacy of a Hepatitis E Vaccine. N Engl J Med.,2015;372:914-22. (IF=176.079)
2. Fengcai Zhu#, Jun Zhang#, Chen Zhou, Xue-feng Zhang, Shou-jie Huang, Hua Wang, Chang-lin Yang, Han-min Jiang, Jia-ping Cai, Yi-jun Wang, Xing Ai, Yue-mei Hu, Quan Tang, Yang-ling Xian, Ting Wu, Yi-min Li, Ji Miao, Hun-hon Ng, James Wai-kuo Shih, Ning-shao Xia*. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial. Lancet, 2010,376:895-902. (IF=202.731)
3. Zhu F#, Zhuang C#, Chu K#, Zhang L#, Zhao H#, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y*, Zhang T*, Ye X*, Li C*, Wu T*, Zhang J*, Xia NS*. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med., 2022 Aug;10(8):749-760. (IF=102.642)
4. Zhao FH#, Wu T#, Hu YM,# Wei LH#, Li MQ#, Huang WJ#, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J*, Qiao YL*, Xia NS*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis., 2022 Dec;22(12):1756-1768. (IF=71.421)
5. Mo Z-J, Huang S-J, Qiu L-X, Li C-G, Yu X-J, Li M-Q, et al. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial. Lancet Reg Health West Pac. 2023（Accepted）
6. Kai C, Zhao B, Wei H, Ya L, Li Z, Chang Y, Han J, Xia Z, Qi C, Dong L, Hong P, Yue H, Feng Z, Qiu Z, Guang S, Ying S, Shou H, Hui P, Ting W, Yue H, Jun Z, Feng Z, Ning X. Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial. Lancet Reg Health West Pac. 2022（Accepted）
7. Huang Z, Su Y, Zhang T, Xia N*. A review of the safety and efficacy of current COVID-19 vaccines. Front Med., 2022 Feb;16(1):39-55. (IF=5.058)
8. Huang Y, Tang J, Wang H, Yu H, Song Q, Guo X, Li C, Wang J, Liang C, Li S, Li S, Lin Z, Chen Q, Zhong G, Zhuang S, Su Y, Li T, Wu T*, Ge S*, Zhang J*, Xia N. Pre-existing maternal IgG antibodies as a protective factor against congenital cytomegalovirus infection: A mother-child prospective cohort study. EBioMedicine. 2022 Feb 17;77:103885. (IF=11.205)
9. Zhuang C, Liu X, Chen Q, Sun Y, Su Y, Huang S, Wu T* and Xia N. Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Front Microbiol. 2022 Feb 13:828806. (IF=6.064)
10. Huang ZH#, Lu GY#, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, Huang SJ, Wu T, Yuan Q, Wang YB*, Su YY*, Zhang J, Xia NS. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer. 2022 Mar 17;22(1):287. (IF=4.638)
11. Chen Q, Zhu K, Liu X, Zhuang C, Huang X, Huang Y, Yao X, Quan J, Lin H, Huang S, Su Y*, Wu T*, Zhang J, Xia N. The Protection Provided by Naturally Acquired Antibodies against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Emerg Microbes Infect. 2022 Feb 23:1-44. （IF=19.568）
12. Huang Y#, Wang H#, Li T#, Li C#, Tang J, Yu H, Guo X, Song Q, Wei F, Wang J, Liang C, Zheng F, Li H, Li H, Wu H, Lu Z, Su Y, Wu T, Ge S*, Fu T-M*, Zhang J*, Xia N. Comparison of detection strategies for screening and confirming congenital cytomegalovirus infection in newborns in a highly seroprevalent population: a mother-child cohort study. Lancet Reg Health West Pac. 2021 Jun 9;12:100182. (IF=8.559)
13. Yao X, Chen W, Zhao C, Wei L, Hu Y, Li M, Lin Z, Lin B, Liu X, Hong Y, Li Q, Pan Q, Zhang X, Li M, Zhao Y, Zhang L, Xu H, Hu F, Zhao J, Huang Y, Sheng W, Zheng Y, Hu S, Su Y, Huang S, Pan H, Zhao F*, Qiao Y*, Wu T*, Zhang J*, Xia N*. Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study. Lancet Reg Health West Pac. 2021 Jul 16;13:100196. (IF=8.559)
14. Huang Y, Li T, Yu H, Tang J, Song Q, Guo X, Wang H, Li C, Wang J, Liang C, Yao X, Qiu L, Zhuang C, Bi Z, Su Y, Wu T, Ge S*, Zhang J*. Maternal CMV seroprevalence rate in early gestation and congenital cytomegalovirus infection in a Chinese population. Emerg Microbes Infect. 2021 Dec;10(1):1824-1831.（IF=19.568）
15. Zhuang CL#, Lin ZJ#, Bi ZF, Qiu LX, Hu FF, Liu XH, Lin BZ, Su YY, Pan HR, Zhang TY, Huang SJ, Hu YM, Qiao YL, Zhu FC*, Wu T*, Zhang J, Xia NS. Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerg Microbes Infect. 2021 Dec;10(1):365-375. （IF=19.568）
16. Wei F#, Su Y#, Cui X, Yu X, Li Y, Song Q, Yin K, Huang S, Li M, Zhang J, Wu T*, Xia N. Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China. Emerg Infect Dis. 2020 Oct;26(10):2387-2393.（IF=16.126）
17. Zhang H-J#, Su Y-Y#, Xu S-L#, Chen G-Q, Li C-C, Jiang R-J, Liu R-H, Ge S-X, Zhang J, Xia N-S, Quan T*. Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Close Contacts of Coronavirus Disease 2019 (COVID-19) Patients: A Seroepidemiological Study. Clin Infect Dis. 2021 Aug 2;73(3):553-554.（IF=20.999）
18. Zhao J#, Yuan Q#, Wang H#, Liu W#, Liao X#, Su Y#, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S*, Liu L*, Zhang J*, Xia N, Zhang Z*. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (IF=20.999)
19. Li W#, Su YY#, Zhi SS#, Huang J, Zhuang CL, Bai WZ, Wan Y, Meng XR, Zhang L, Zhou YB, Luo YY, Ge SX*, Chen YK*, Ma Y*.Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol Infect. 2020 Nov;26(11):1556. e1-1556.e6.（IF=13.310）
20. Wei LH#, Su YY#, Hu YM, Li RC, Chen W, Pan QJ, Zhang X, Zhao FH, Zhao YQ, Li Q, Hong Y, Zhao C, Li MQ, Liu WY, Li CH, Guo DP, Ke LD, Lin BZ, Lin ZJ, Chen S, Sheng W, Zheng ZZ, Zhuang SJ, Zhu FC, Pan HR, Li YM, Huang SJ, Zhang J, Qiao YL*, Wu T*, Xia NS. Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial. Clin Microbiol Infect. 2020 Aug;26(8):1069-1075. (IF=13.310)
21. Lou B#, Li TD#, Zheng SF#, Su YY#, Li ZY, Liu W, Yu F, Ge SX, Zou QD, Yuan Q, Lin S, Hong CM, Yao XY, Zhang XJ, Wu DH, Zhou GL, Hou WH, Li TT, Zhang YL, Zhang SY, Fan J, Zhang J, Xia NS, Chen Y*. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020 Aug 27;56(2):2000763. (IF=33.795)
22. Lin CQ, Slama J, Gonzalez P, Goodman MT, Xia NS, Kreimer AR, Wu T, Hessol NA, Shvetsov Y, Ortiz AP, Grinsztejn B, Moscicki AB, Heard I, Losa MDG, Kojic EM, van der Loeff MFS, Wei FX, Longatto-Filho A, Mbulawa ZA, Palefsky JM, Sohn AH, Hernandez BY, Robison K, Simpson S, Conley LJ, de Pokomandy A, van der Sande MAB, Mandishora RSD, Volpini LPB, Pierangeli A, Romero B, Wilkin T, Franceschi S, Hidalgo-Tenorio C, Ramautarsing RA, Park IU, Tso FK, Godbole S, D'Hauwers KWM, Sehnal B, Menezes LJ, Heraclio SA, Clifford GM. Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis. 2019 Aug;19(8):880-891. （IF=71.421）
23. Qiao Y-L#*, Wu T#, Li R-C#, Hu Y-M#, Wei L-H#, Li C-G#, Chen W#, Huang S-J, Zhao F-H, Li M-Q, Pan Q-J, Zhang X, Li Q, Hong Y, Zhao C, Zhang W-H, Li Y-P, Chu K, Li M, Jiang Y-F, Li J, Zhao H, Lin Z-J, Cui X-L, Liu W-Y, Li C-H, Guo D-P, Ke L-D, Wu X, Tang J, Gao G-Q, Li B-Y, Zhao B, Zheng F-X, Dai C-H, Guo M, Zhao J, Su Y-Y, Wang J-Z, Zhu F-C, Li S-W, Pan H-R, Li Y-M, Zhang J*, Xia N-S*. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145-153. （IF=11.816）
24. Wei FX, Su YY, Yao XM, Cui XL, Bian LH, Yin K, Yu XJ, Zhuang CL, Bi ZF, Huang SJ, Li MQ, Wu T, Xia NS, Zhang J*. Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study. Int J Cancer. 2019 Aug 1;145(3):807-816. （IF=7.316）
25. Chen Z#, Lin S#, Duan J#, Luo Y, Wang S, Gan Z, Yi H, Wu T, Huang S*, Zhang Q*, Lv H*. Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial. Clin Microbiol Infect. 2019 Sep;25(9):1133-1139. （IF=13.31）
26. Wang KH#, Zhou LZ#, Zhang X#, Song CL, Chen TT, Li JJ, Zheng MH, Wang YB, Zheng QB, Zheng ZZ, Yu H, Wu T, Gu Y, Zhang J, Zhao QJ*, Li SW*, Xia NS. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. Antiviral Res. 2019 Apr;164:154-161. (IF=10.103)
（五）本组优势
1. 日常工作中会与国内顶级医疗机构及多省市卫生机构（疾控中心，妇幼保健院等）建立友好合作关系；
2. 研究生期间可以到全国多个项目现场参与现场工作，积累人脉与工作经验；
3. 有机会参加多项国内外大型会议并作发言；
4. 本组就业形势好，毕业生去向包括国际癌症研究所（IARC）、国家药审中心（CDE）、高校、大型药企、CRO公司、省级疾控中心、三甲医院等，职业涵盖博后、高校教师、医院科研岗、项目经理、CRA、生物统计师、医学专员、公务员等；
5. 因本组承担项目主要为大型前瞻性人群研究，在导师的指导下，由研究生主导完成从研究设计、项目；开展至数据分析及论文撰写的工作，富有挑战且具有科研意义，同时可从中获得较为丰富的科研成果；
6. 优秀者可在研究生二年级申请硕博连读；
7. 团结友好、互帮互助、温暖有爱的团队氛围，导师指导细致全面。
（六）招生要求
预防医学专业优先
